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Abstract
Purpose: Multiple studies have shown that adherence to ad-
juvant hormonal therapy in women with breast cancer is subop-
timal. Measurements of compliance with self-report, pill counts,
and/or pharmacy records are susceptible to bias. We assessed
the feasibility of using a urine anastrozole assay as an objective
biomarker of nonadherence to anastrozole treatment.
Patients and Methods: We recruited consecutive post-
menopausal women, age  18 years, with hormone-sensitive
nonmetastatic breast cancer who were prescribed anastrozole
at least 3 months before enrollment. Each completed a short
survey to gather information on demographics, anastrozole
compliance history, and self-reported medication history, tumor
characteristics, and treatment received. A single, random 15-mL
urine sample was collected and tested for the presence of anas-
trozole using a previously validated assay. Patients were told
they were part of a study to determine if anastrozole could be
detected in the urine.
Results: Among 96 participants, mean age was 63.7 years
(range, 51 to 70 years). The population was diverse, with 56.5%
white, 57.6% US born, 59.8% unemployed, and 56.6% college
educated. Prior treatment included chemotherapy (50%) and/or
radiotherapy (58.7%). Mean duration of anastrozole treatment
was 2.2 years (standard deviation, 1.6). Four participants re-
ported nonadherence and declined to submit urine samples, and
two had no detectable level of anastrozole (six of 96; 6.3%).
Detectable levels among adherent women ranged from 49.3 to
632.8 ng/mL.
Conclusion: We demonstrated that collection of urine tomea-
sure anastrozole levels is feasible and reliable. Identifying bio-
markers to measure adherence is critical for studies investigating
interventions to improve hormonal therapy compliance.
Introduction
Adjuvant hormonal therapy (tamoxifen and aromatase inhibi-
tors) reduces mortality in women with hormone-sensitive, non-
metastatic breast cancer.1,2 Tamoxifen, in use for more than
three decades, has been shown to reduce risk of breast cancer
recurrence and mortality by as much as 41% and 34%, respec-
tively.2 In postmenopausal women with breast cancer, aroma-
tase inhibitors are also effective at reducing recurrence and
decreasing mortality.1 However, the full benefits of these treat-
ments are best achieved if they are taken for the full 5-year
course, as prescribed.3 For many reasons, some women do not
initiate adjuvant endocrine treatment,4-9 take themedication
80% of the time, or discontinue their therapy early.3,6,8-11 This
results in a reduction of the full survival benefit.12
Determining adherence to adjuvant hormonal therapy and
assessing treatment discontinuation can be methodologically
challenging, because many measures result in bias.13 Patient
self-reports and medical record reviews are susceptible to mis-
representation and tend to overestimate adherence.14-16 Pill
counts and electronic pill bottles have limitations, because they
alter behavior, and patients can switch medicine between bot-
tles or throw away the pills to seem adherent.14,17 Electronic
pharmacy data abstraction is the least subject to bias; however,
the reasons for discontinuation are unknown, and patients can
switch pharmacies and seem as if they have discontinued. One
possible approach is to use a biomarker such as plasma or
urine drug or metabolite levels to determine hormonal treat-
ment adherence.14,18
Athletes use aromatase inhibitors to reverse or prevent
gynecomastia, an adverse effect of certain performance-
enhancing anabolic androgenic steroids.18 In response to a
growing underground movement of aromatase inhibitor
misuse, the International Olympic Committee and the
World Anti-Doping Agency added hormone antagonists and
modulators to their list of prohibited substances.19 As a re-
sult, assays for these substances are commercially available
through World Anti-Doping Agency–approved laboratories
around the world. These tests are highly sensitive at detect-
ing low levels of drug in the urine18 of professional and
Olympic athletes,20 but they have not previously been used
as a measure of adherence to adjuvant hormonal treatment
among patients with breast cancer.
The purpose of this study was to assess the feasibility and
reliability of using a urine anastrozole assay as a biomarker for
early discontinuation of adjuvant anastrozole therapy in women
with breast cancer. We hypothesized that adherence deter-
mined by the urine anastrozole level would be less than self-
reported adherence.
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Patients and Methods
Study Design and Recruitment
Participants were all under the care of medical oncologists at the
Herbert Irving Comprehensive Cancer Center at Columbia
University (New York, NY). Patients were consecutively en-
rolled after being prescreened for eligibility on a daily basis by
their treating physician between September 2010 and Septem-
ber 2011. As patients presented in the clinic, each was asked to
participate in a study to determine if anastrozole could be de-
tected in the urine. Specimens were collected at the time of
enrollment with no advance knowledge of testing. Written in-
formed consent andHealth Insurance Portability and Account-
ability Act authorization were obtained from all participants,
and all procedures were approved by the Columbia University
Medical Center Institution Review Board and Privacy Office.
Eligibility Criteria
Postmenopausal women age 18 years diagnosed with stages I
to III primary, invasive, or secondary breast cancer, with estro-
gen receptor– and/or progesterone receptor–positive tumors,
were included. Participants had been prescribed anastrozole for
at least 3 months before enrollment and were within the 5-year
planned course for the use of this medication. Women with
noninvasive breast cancer or metastatic disease were excluded,
as were women who were unable to provide informed consent
because of moderate or severe dementia.
Study Procedures
A short questionnaire was administered at the time of enroll-
ment. Questions included a brief history of anastrozole use
(number of years taking anastrozole and days since last anastro-
zole dose was taken), sociodemographic information (age, race/
ethnicity, nativity, educational attainment, employment status,
annual household income, and medical insurance and prescrip-
tion drug coverage information), and breast cancer history (tu-
mor stage, type of surgery, and adjuvant treatment received
[radiation and chemotherapy]).
Each participant provided a single, random 15-mL urine
sample. All urine samples were delivered to the Biospecimen
Repository of the Herbert Irving Comprehensive Cancer Cen-
ter, then frozen to 70°C, packaged, and shipped in batches
overnight on dry ice to the Sports Medicine Research and Test-
ing Laboratory (Salt Lake City, UT) for analysis.
Urine Anastrozole Biomarker and Analysis
Described chemically as 1,3-benzenediacetonitrile, a, a, a’, a’-
tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl), anastrozole me-
tabolizes to form triazole, a glucuronide conjugate of hydroxy-
anastrozole, and a glucuronide conjugate of anastrozole itself in
human plasma and urine. Only tamoxifen and estrogen-con-
taining therapies are known to diminish the pharmacologic
action of anastrozole. Food reduces but does not interfere with
the overall extent of absorption. The mean elimination half-life
of anastrozole is 50 hours.21
Extraction of urine samples was performed by buffering to
pH7 and incubating with-glucuronidase (Roche, Pleasanton,
CA). After incubation, samples were buffered for extraction
with 0.75 mL of a 20% (w/v) solution of 1:1 K2CO3/KHCO3,
and a liquid-liquid extraction was performed using 6 mL of
methyl tert-butyl ether. The methyl tert-butyl ether layer was
evaporated to dryness and reconstituted in mobile phase for
liquid chromatography–mass spectrometry analysis. Samples
were analyzed on a Thermo Finnigan TSQ Quantum mass
spectrometer (Thermo Electron, Waltham, MA) coupled to a
Finnigan Surveyor LC system (Thermo Electron). The mobile
phases were 0.1% formic acid in water and methanol. The
linear range of the assay was established at 2.5 to 750 ng/mL.
The limits of detection and quantitation were established at 0.5
and 2.5 ng/mL, respectively. For a batch to be considered ac-
ceptable, at least 75% of the curve points were required to
quantitate within 15% of nominal value and the quality control
(QC) reagents to quantitate within 10% of their nominal value.
Two QC standards were analyzed with every batch: low QC
standard at 50 ng/mL and high QC standard at 500 ng/mL. All
QC measurements were recorded and analyzed to determine
variability in the assay over time. Over the last year, the coeffi-
cients of variation for the low and high QC standards were
determined to be 5.9% and 1.8%, respectively. The aromatase
inhibitor assay panel included measurement of all three aroma-
tase inhibitors (anastrozole, letrozole, and exemestane); how-
ever, only anastrozole was reported for the purpose of this pilot
study.
Statistical Analyses
Descriptive statistics were generated. For continuous variables,
means and standard deviations (SDs) were computed. For cat-
egorical variables, frequency tables were produced. Nonadher-
ence to anastrozole treatment was based on undetectable levels
of anastrozole in the urine (0.0 ng/mL). All analyses were per-
formed using PASW version 18 (IBM SPSS, Chicago, IL).
Results
A total of 96 eligible women were identified. Four participants
declined to participate and provide urine samples because of
self-reported nonadherence to prescribed anastrozole.Mean age
of participants was 63.7 years (SD, 11.1), and a majority were
between the ages of 51 to 70 years (69.5%; Table 1). Only
slightly more than half (56.5%) were white, 57.6% were born
in the United States, 60% had a college level or higher educa-
tion, and 59.8% were not currently employed. Nearly one
quarter reported an annual household income in excess of
$70,000, all had medical health insurance (public or private),
and 96.7% had prescription drug coverage. Approximately half
the patients had been treated with chemotherapy and radiation
therapy (50.0% and 58.7%, respectively).
Overall, six (6.3%) of 96 participants were nonadherent to
their hormonal therapy, and of these, two (2.1%) were demon-
strated to be nonadherent (0.0 ng/mL) by the assay. Detectable
levels of anastrozole ranged from 49.3 to 632.8 ng/mL (mean,
204.5 ng/mL; SD, 121.2). More than one third of participants
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reported taking anastrozole for 1 year, with a mean duration
of 2.2 years (SD, 1.6; Table 1). Nearly all participants (97.8%)
reported taking their last anastrozole pill the day of the inter-
view or the day before (Fig 1), including the two participants
with undetectable levels of anastrozole in their urine. However,
one patient who reported last taking the pill 3 days before and
another 20 days before still had detectable levels in the urine.
The self-reported mean number of days since the last anastro-
zole pill was taken was 0.6 (SD, 2.1).
Discussion
Results of this study demonstrate the feasibility and reliability
of using urine anastrozole levels to identify women who are
noncompliant with their prescribed adjuvant hormonal ther-
apy. Two participants who reported taking their anastrozole
either the same day as the interview or the day before, in fact,
had no detectable level of anastrozole in their urine, whereas
others whose last pill was reportedly taken 3 and 20 days before,
respectively, each had detectable level of drug in the urine. This
is not surprising, because the elimination half-life of anastrozole
is 2 days. On the basis of these findings, measuring anastro-
zole levels in the urine of women with hormone-sensitive breast
cancer for whom anastrozole has been prescribed may be an
unbiased measure of anastrozole adherence.
Medication adherence is an area of concern in many dis-
eases. For some, biomarkers that evaluate clinical response to
Table 1. Patient Sociodemographic and Clinical Characteris-













No. of years taking anastrozole





 5 1 1.1
No. of days since last pill taken
0 58 63.7
1 31 34.1









African American/black 17 18.5





United States 53 57.6
Non–United States 39 42.4
Educational attainment
 Grade school 12 13.2
High school 25 27.5
College 28 30.8
Graduate school 26 28.6
Employment status
Employed 37 40.2
Not employed 55 59.8






 $15,000 16 17.4
$15,001 to $30,000 12 13.0
$30,001 to $50,000 9 9.8
$50,001 to $70,000 8 8.7
 $70,000 22 23.9
Medical health insurance 92 100.0












Radiation therapy 54 58.7
* For postmenopausal women with hormone-sensitive breast cancer for whom
anatrozole was prescribed between August 2010 and March 2011.
† Self-reported.
‡ Categories were not mutually exclusive; total is greater than 100%.
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treatment are also used to measure adherence in clinical trials
and in practice. For example, to suppress viral replication and
avoid the emergence of resistance to highly active antiretroviral
therapy, patients with AIDS need to achieve 95% adherence
to a complex dosing schedule of multiple medications.22 Bio-
markers such as CD4 counts and viral load tests are used as to
assess adherence and as end points in intervention trials to im-
prove adherence. Although using an indirect method of this
kind can be relatively simple and easy to perform, a disadvan-
tage is that factors unrelated to adherence can affect the bio-
marker irrespective of adherence.14
No other studies to date to our knowledge have used urine
aromatase inhibitor levels to assess treatment adherence. One
research team in Austria developed and evaluated the usefulness
of an assay that simultaneously quantified tamoxifen, anastro-
zole, and letrozole in human plasma. Of 310 patients with
breast cancer undergoing endocrine therapy, eight were found
to have unquantifiable levels of the prescribed antiestrogen drug
in their system (nonadherence rate, 2.6%).23 In comparison,
our rate of nonadherence of 6% was more than twice that
reported by Beer et al23 but not inconsistent with other medi-
cation adherence studies using pill counts, medical record ab-
straction, or pharmacy data, given that this was a one-time
assessment.3,4,10,11,15,16 These more traditional methods, how-
ever, are exquisitely sensitive to measurement error, whereas
with urine testing, false-negative tests would be highly unusual.
There are several limitations to our study. Because of genetic
and physiologic factors influencing anastrozole pharmokinetics
and excretion and limited information related to anastrozole-tak-
ing habits, we were unable to interpret the range of anastrozole
results that varied widely in our study. We were thus unable to
determine exactly when the last pill was taken, and so, we can only
state conclusively that the participants with no anastrozole in the
urine had discontinued treatment in the past. However, a false-
negative test would be highly unusual given the sensitivity of the
test. Physicians were not queried to determine if the patient re-
vealed nonadherence during the course of the visit. The small sam-
ple size and self-selection, although limited, may have reduced our
nonadherence rate. All participants were treated in a university
hospital where issues related to compliance and adherence are dis-
cussed, so the nonadherence rate may be an underestimation and
may not be generalizable to other settings. Furthermore, those
patients who discontinue treatment many times leave the care of
the oncologist and would not be available for study recruitment.
Additionally, we used a strict criterion for determination of non-
adherence (0.0 ng/mL). As observed by Beer et al,23 levels at the
lower end of the distribution higher than our cutoff value may
represent irregular medication intake, but this would require fur-
ther investigation. This assay is a qualitative test used to detect
illegal doping in the sports industry and has not been clinically
validated as a measure of aromatase inhibitor compliance among
patients with breast cancer.
Testing for the presence of aromatase inhibitors in the urine is a
reliable, feasible, and objective alternative to patient self-report and
methods of determining adjuvant hormonal treatment adherence.
Identification of early discontinuation may provide researchers
with an unbiased outcomemeasure onwhich to base interventions
thatmay increase the completion rate of this treatment and reduce
breast cancer recurrence andmortality. Future clinical validationof
this test may also provide physicians with a valuable tool with
which to guide breast cancer treatment.
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Figure 1. Comparison of anastrozole level and self-reported number of
days since last anastrozole pill was taken (n  91).
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